通过破坏性宏分子抑制剂加速分解IgE受体复合体
Beomkyu Kim1, Alexander Eggel, Svetlana S Tarchevskaya
1Department of Structural Biology, Stanford University School of Medicine, Stanford, California 94305, USA.
Nature
|October 30, 2012
概括
一种新型的工程蛋白抑制剂,DARPin E2_79,积极解离预先形成的IgE-FcεRI复合体,提供一种超出传统竞争性抑制的新策略来阻止过敏反应.
科学领域:
- 免疫学 免疫学 免疫学
- 过敏研究 研究过敏
- 结构生物学 结构生物学
背景情况:
- 免疫球蛋白E (IgE) 抗体结合于巨细胞和基细胞上的高亲密性IgE Fc受体 (FcεRI),启动过敏炎症反应.
- 现有的抗IgE疗法,如奥马利祖马布向IgE-FcεRI结合,但不能破坏缓慢解离的预成型复合体.
- IgE-Fc的结构灵活性表明非经典的抑制机制是可能的.
研究的目的:
- 研究一种工程蛋白抑制剂DARPin E2_79对IgE-FcεRI相互作用的作用机制.
- 确定DARPin E2_79是否可以破坏预先形成的IgE-FcεRI复合体.
- 阐明DARPin E2_79的抑制功能的结构和运动基础.
主要方法:
- 进行X射线晶体学以确定E2_79-IgE-Fc(3-4) 复合物的结构.
- 位点定向的突变发生以探测抑制剂的结合和功能.
- 定量运动建模以分析解离机制.
主要成果:
- DARPin E2_79不仅阻断IgE-FcεRI相互作用,而且积极促进预制复合物的解离.
- 结构分析显示了E2_79的两个潜在结合部位,其中一个部位显示与受体的部分硬质重叠.
- 突变研究和动力学建模证实,E2_79主要通过第2位点促进分离.
结论:
- 高亲和度IgE-FcεRI复合体可以被积极分离以抑制过敏反应.
- DARPin E2_79通过积极破坏稳定的IgE-FcεRI复合体,为过敏疾病提供了一种新的治疗策略.
- 大分子抑制剂可能是积极破坏稳定的蛋白质-蛋白质相互作用的一般方法.
更多相关视频
04:15Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
Published on: February 2, 2024
2.2K
14:18Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
2.2K
相关概念视频
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
Regulation of the Unfolded Protein Response
2.2K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.2K
TGF - β Signaling Pathway
7.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
GPCR Desensitization
6.1K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.1K
Desensitization and Tachyphylaxis
3.4K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.4K
